The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Biomarkers of Alzheimer disease in plasma
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Boushey, C. J. (1995) · JAMA · doi:10.1001/jama.1995.03530130055028 · Cited by 3,584
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Statins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Wolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“A autoantibodies Passive and active immunization against A 42 reduced cerebral amyloid deposition in APP transgenic mice,(24,25) with suggestive related effects in a human clinical trial of active immunization.(26,27) Based on these results, it was hypothesized that people possessing auto-”
BackgroundSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“ningoencephalitis as a side effect of immunization (18 of 298 on active treatment).(31)”
BackgroundHofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van Harskamp, F., van Duijn, C. N., Van Broeckhoven, C., & Grobbee, D. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09328-2 · Cited by 1,062
Cholesterol metabolism in the brain
Dietschy, J. M., & Turley, S. D. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00003 · Cited by 906
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
Clinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777
Boushey, C. J. (1995) · JAMA · doi:10.1001/jama.274.13.1049 · Cited by 767
ALLANBUTTERFIELD, D., CASTEGNA, A., LAUDERBACK, C., & DRAKE, J. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00340-2 · Cited by 715
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 669
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
(1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 666
Praticò, D., Clark, C. M., Liun, F., Lee, V. Y.-M., & Trojanowski, J. Q. (2002) · Archives of Neurology · doi:10.1001/archneur.59.6.972 · Cited by 584
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582
DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563
Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., Wolfson, C., & McDowell, I. (2002) · Archives of Neurology · doi:10.1001/archneur.59.2.223 · Cited by 516
Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
Yaffe, K., Barrett-Connor, E., Lin, F., & Grady, D. (2002) · Archives of Neurology · doi:10.1001/archneur.59.3.378 · Cited by 439
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434 · cited 1×
“Mayeux [13] 6E10 (A 1–16) R162/R165 AD at baseline Incident AD Nondemented 79 86 365 43.”
BackgroundSimons, M., Schwärzler, F., Lütjohann, D., Von Bergmann, K., Beyreuther, K., Dichgans, J., Wormstall, H., Hartmann, T., & Schulz, J. B. (2002) · Annals of Neurology · doi:10.1002/ana.10292 · Cited by 415
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405
Licastro, F., Pedrini, S., Caputo, L., Annoni, G., Davis, L. J., Ferri, C., Casadei, V., & Grimaldi, L. M. E. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00226-x · Cited by 400
Lütjohann, D., Papassotiropoulos, A., Björkhem, I., Locatelli, S., Bagli, M., Oehring, R. D., Schlegel, U., Jessen, F., Rao, M. L., von Bergmann, K., et al. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32052-6 · Cited by 382
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
Gomez‐Isla, T., West, H. L., Rebeck, G. W., Harr, S. D., Growdon, J. H., Locascio, J. J., Perls, T. T., Lipsitz, L. A., & Hyman, B. T. (1996) · Annals of Neurology · doi:10.1002/ana.410390110 · Cited by 378
A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease
Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G., Burkhard, P., Hochstrasser, D. F., & Sanchez, J. (2003) · PROTEOMICS · doi:10.1002/pmic.200300470 · Cited by 374
Jarvik, G. P., Wijsman, E. M., Kukull, W. A., Schellenberg, G. D., Yu, C., & Larson, E. B. (1995) · Neurology · doi:10.1212/wnl.45.6.1092 · Cited by 370
Tarkowski, E., Blennow, K., Wallin, A., & Tarkowski, A. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020568013953 · Cited by 349
Pratic�, D., Clark, C. M., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & FitzGerald, G. A. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200011)48:5<809::aid-ana19>3.0.co;2-9 · Cited by 348
(1993) · PubMed · Cited by 330
Cracowski, J.-L., Durand, T., & Bessard, G. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02053-9 · Cited by 330
Matsuoka, Y., Saito, M., LaFrancois, J., Saito, M., Gaynor, K., Olm, V., Wang, L., Casey, E., Lu, Y., Shiratori, C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00029.2003 · Cited by 326
Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301
Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease
Hock, C., Konietzko, U., Papassotiropoulos, A., Wollmer, A., Streffer, J., von Rotz, R. C., Davey, G., Moritz, E., & Nitsch, R. M. (2002) · Nature Medicine · doi:10.1038/nm783 · Cited by 284
Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease: The Framingham Study
Tan, Z. S., Seshadri, S., Beiser, A., Wilson, P. W. F., Kiel, D. P., Tocco, M., D'Agostino, R. B., & Wolf, P. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1053 · Cited by 280
Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 257
Self-citationInflammation and therapeutic vaccination in CNS diseases
Weiner, H. L., & Selkoe, D. J. (2002) · Nature · doi:10.1038/nature01325 · Cited by 255
Increased CSF F 2 -isoprostane concentration in probable AD
Montine, T. J., Beal, M. F., Cudkowicz, M. E., O’Donnell, H., Margolin, R. A., McFarland, L., Bachrach, A. F., Zackert, W. E., Roberts, L. J., & Morrow, J. D. (1999) · Neurology · doi:10.1212/wnl.52.3.562 · Cited by 251
McGrath, L. T. (2001) · QJM · doi:10.1093/qjmed/94.9.485 · Cited by 251
Lipid Peroxidation and Free Radical Scavengers in Alzheimer’s Disease
Jeandel, C., Nicolas, M. B., Dubois, F., Nabet-Belleville, F., Penin, F., & Cuny, G. (1989) · Gerontology · doi:10.1159/000213037 · Cited by 250
Ordovas, J. M., Litwack-Klein, L., Wilson, P. W., Schaefer, M. M., & Schaefer, E. J. (1987) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38690-9 · Cited by 238
Reduced levels of amyloid β-peptide antibody in Alzheimer disease
Du, Y., Dodel, R., Hampel, H., Buerger, K., Lin, S., Eastwood, B., Bales, K., Gao, F., Moeller, H. –., Oertel, W., et al. (2001) · Neurology · doi:10.1212/wnl.57.5.801 · Cited by 235
Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease
Foy, C. J. (1999) · QJM · doi:10.1093/qjmed/92.1.39 · Cited by 235
Mehta, P. D., Pirttila, T., Patrick, B. A., Barshatzky, M., & Mehta, S. P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01754-2 · Cited by 231
24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia
Papassotiropoulos, A., Lütjohann, D., Bagli, M., Locatelli, S., Jessen, F., Buschfort, R., Ptok, U., Björkhem, I., von Bergmann, K., & Heun, R. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00050-4 · Cited by 231
Ghersi‐Egea, J. ‐., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., & Fenstermacher, J. D. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020880.x · Cited by 222 · cited 1×
“Nonetheless, animal studies indicate that A can pass between the CSF and plasma compartments.(21,22) Peripherally administered compounds with high-affinity binding to A increased the flux of A from the brain and CSF to the plasma in APP transgenic mice.”
BackgroundHomocysteine and Neurologic Disease
Diaz-Arrastia, R. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1422 · Cited by 218
Evans, R. M., Emsley, C. L., Gao, S., Sahota, A., Hall, K. S., Farlow, M. R., & Hendrie, H. (2000) · Neurology · doi:10.1212/wnl.54.1.240 · Cited by 209
Plasma Concentrations of Vitamins A and E and Carotenoids in Alzheimer's Disease
ZAMAN, Z., ROCHE, S., FIELDEN, P., FROST, P. G., NIRIELLA, D. C., & CAYLEY, A. C. D. (1992) · Age and Ageing · doi:10.1093/ageing/21.2.91 · Cited by 202
Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration
Butterfield, D. A., Boyd‐Kimball, D., & Castegna, A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01948.x · Cited by 183
Reduction in Levels of 24S-Hydroxycholesterol by Statin Treatment in Patients With Alzheimer Disease
Vega, G. L., Weiner, M. F., Lipton, A. M., von Bergmann, K., Lütjohann, D., Moore, C., & Svetlik, D. (2003) · Archives of Neurology · doi:10.1001/archneur.60.4.510 · Cited by 172
Locatelli, S., Lütjohann, D., Schmidt, H., Otto, C., Beisiegel†, U., & von Bergmann, K. (2002) · Archives of Neurology · doi:10.1001/archneur.59.2.213 · Cited by 169
Mitochondrial involvement in Alzheimer’s disease
Bonilla, E., Tanji, K., Hirano, M., Vu, T. H., DiMauro, S., & Schon, E. A. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00165-0 · Cited by 169
APOE genotype, plasma lipids, lipoproteins, and AD in community elderly
Romas, S. N., Tang, M.-X., Berglund, L., & Mayeux, R. (1999) · Neurology · doi:10.1212/wnl.53.3.517 · Cited by 169
Kálmán, J., Juhász, A., Laird, G., Dickens, P., Járdánházy, T., Rimanóczy, A., Boncz, I., Parry-Jones, W. L. I., & Janka, Z. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1997.tb00275.x · Cited by 167
Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid
Teunissen, C. E., de Vente, J., Steinbusch, H. W. M., & De Bruijn, C. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00328-1 · Cited by 166
Leoni, V., Masterman, T., Patel, P., Meaney, S., Diczfalusy, U., & Björkhem, I. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200434-jlr200 · Cited by 165
Circulating cytokines in Alzheimer's disease
Singh, V. K., & Guthikonda, P. (1997) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00023-x · Cited by 163
Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome
Schupf, N., Patel, B. N., Silverman, W. P., Zigman, W. B., Zhong, N., Tycko, B., Mehta, P. D., & Mayeux, R. P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01657-3 · Cited by 161
Schönknecht, P., Lütjohann, D., Pantel, J., Bardenheuer, H., Hartmann, T., von Bergmann, K., Beyreuther, K., & Schröder, J. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00164-7 · Cited by 159
Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease
Montine, T. J., Quinn, J. F., Milatović, D., Silbert, L. C., Dang, T. N. T., Sanchez, S. C., Terry, E. S., Roberts, L. J., Kaye, J. A., & Morrow, J. D. (2002) · Annals of Neurology · doi:10.1002/ana.10272 · Cited by 157
Amyloid β protein in plasma from patients with sporadic Alzheimer's disease
Tamaoka, A., Fukushima, T., Sawamura, N., Ishikawa, K., Oguni, E., Komatsuzaki, Y., & Shoji, S. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00143-8 · Cited by 156
Blood Pressure, Cognitive Functions, and Prevention of Dementias in Older Patients With Hypertension
Birkenhäger, W. H., Forette, F., Seux, M., Wang, J.-G., & Staessen, J. A. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.2.152 · Cited by 156
Polidori, M. C., & Mecocci, P. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4608 · Cited by 148
Schiele, F., Bacquer, D. D., Vincent‐Viry, M., Beisiegel†, U., Ehnholm, C., Evans, A., Kafatos, A., Martins, M. C., Sans, S., Sass, C., et al. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00501-8 · Cited by 146
Autoantibodies to amyloid-? and Alzheimer's disease
Hyman, B. T., Smith, C. R., Buldyrev, I., Whelan, C. M., Brown, H., Tang, M., & Mayeux, R. P. (2001) · Annals of Neurology · doi:10.1002/ana.1061 · Cited by 145
Fukumoto, H., Asami-Odaka, A., Suzuki, N., Shimada, H., Ihara, Y., & Iwatsubo, T. (1996) · Europe PMC (PubMed Central) · Cited by 131
Altered Amyloid Protein Processing in Platelets of Patients With Alzheimer Disease
Rosenberg, R. N., Baskin, F., Fosmire, J. A., Risser, R. C., Adams, P., Svetlik, D. A., Honig, L. S., Cullum, C. M., & Weiner, M. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550140019007 · Cited by 128
Lehtim�ki, T., Pirttil�, T., Mehta, P., Wisniewski, H., Frey, H., & Nikkari, T. (1995) · Human Genetics · doi:10.1007/bf00225071 · Cited by 125
Lipoprotein (a) and stroke: Table 1
Milionis, H. J., WINDER, A. F., & Mikhailidis, D. P. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.7.487 · Cited by 122
Greco, A., Minghetti, L., & Levi, G. (2000) · Neurochemical Research · doi:10.1023/a:1007608615682 · Cited by 117
Platelet APP isoform ratios correlate with declining cognition in AD
Baskin, F., Rosenberg, R. N., Iyer, L., Hynan, L. S., & Cullum, C. M. (2000) · Neurology · doi:10.1212/wnl.54.10.1907 · Cited by 114
Kosaka, T., Imagawa, M., Seki, K., Arai, H., Sasaki, H., Tsuji, S., Asami-Odaka, A., Fukushima, T., Imai, K., & Iwatsubo, T. (1997) · Neurology · doi:10.1212/wnl.48.3.741 · Cited by 113
Maes, M. H. J., Devos, N., Wauters, A., Demedts, P., Maurits, V., Neels, H. M., Bosmans, E., Altamura, C. A., Lin, A., Song, C., et al. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00016-3 · Cited by 112
Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease
Taddei, K., Clarnette, R., Gandy, S., & Martins, R. N. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13394-8 · Cited by 105
Padovani, A., Borroni, B., Colciaghi, F., Pettenati, C., Cottini, E., Agosti, C., Lenzi, G. L., Caltagirone, C., Trabucchi, M., Cattabeni, F., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.1.71 · Cited by 99
Passage of human amyloid β-protein 1–40 across the murine blood-brain barrier
Maness, L. M., Banks, W. A., Podlisny, M. B., Selkoe, D. J., & Kastin, A. J. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00331-9 · Cited by 97
Combination of serum markers related to several mechanisms in Alzheimer’s disease
Teunissen, C. E., Lütjohann, D., von Bergmann, K., Verhey, F. R. J., Vreeling, F. W., Wauters, A., Bosmans, E., Bosma, H., van Boxtel, M. P. J., Maes, M. H. J., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00005-8 · Cited by 97
Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD
Padovani, A., Pastorino, L., Borroni, B., Colciaghi, F., Rozzini, L., Monastero, R., Perez, J., Pettenati, C., Mussi, M., Parrinello, G., et al. (2001) · Neurology · doi:10.1212/wnl.57.12.2243 · Cited by 96
Buxbaum, J. D., Cullen, E. I., & Friedhoff, L. T. (2002) · Frontiers in bioscience · doi:10.2741/a739 · Cited by 94
Mann, D. M. A., Iwatsubo, T., Pickering-Brown, S. M., Owen, F., Saido, T. C., & Perry, R. H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13294-8 · Cited by 91
Serum Creatinine Levels Correlate With Plasma Amyloid β Protein
Arvanitakis, Z., Lucas, J. A., Younkin, L. H., Younkin, S. G., & Graff‐Radford, N. R. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200207000-00009 · Cited by 91
Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease
Solfrizzi, V., Panza, F., D'Introno, A., Colacicco, A. M., Capurso, C., Basile, A. M., & Capurso, A. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.732 · Cited by 90
Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease
Angelis-Stoforidis, P., Scharf, S., Mander, A. G., Vajda, F. J. E., & Christophidis, N. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00136-0 · Cited by 88
Serum cytokine levels in patients with Alzheimer's disease
Chao, C. C., A, T., Hu, S., Crossley, K., Sherman, R. E., Peterson, P. K., & Frey, W. H. (1994) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.1.4.433-436.1994 · Cited by 85
Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease
Scacchi, R., Gambina, G., Ruggeri, M., Martini, M. C., Ferrari, G., Silvestri, M., Schiavon, R., & Corbo, R. M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00889-1 · Cited by 83
Borroni, B., Colciaghi, F., Pastorino, L., Pettenati, C., Cottini, E., Rozzini, L., Monastero, R., Lenzi, G. L., Cattabeni, F., Luca, M. D., et al. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.442 · Cited by 82
Siest, G., Bertrand, P., Qin, B. Y., Herbeth, B., Sérot, J., Masana, L., Ribalta, J., Passmore, A. P., Evans, A., Ferrari, M., et al. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.102 · Cited by 80
Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease
van Duijn, C. M., Albert Hofman, D., & Nagelkerken, L. M. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90666-w · Cited by 80
Bonaccorso, S., Lin, A., Song, C., Verkerk, R. M., Kenis, G., Bosmans, E., Scharpé, S., Vandewoude, M. F. J., Dossche, A., & Maes, M. H. J. (1998) · Aging Clinical and Experimental Research · doi:10.1007/bf03339794 · Cited by 68
Fukumoto, H., Ingelsson, M., Gårevik, N., Wahlund, L.-O., Nukina, N., Yaguchi, Y., Shibata, M., Hyman, B. T., Rebeck, G. W., & Irizarry, M. C. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00088-8 · Cited by 63
Self-citationSerum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study
Slooter, A. J. C., de Knijff, P., Albert Hofman, D., Cruts, M., Breteler, M. M. B., Broeckhoven, C. V., Havekes, L. M., & van Duijn, C. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00339-5 · Cited by 56
Panza, F., Solfrizzi, V., Colacicco, A. M., Basile, A. M., D’Introno, A., Capurso, C. A., Sabba, M., Capurso, S. A., & Capurso, A. (2003) · Neuroreport · doi:10.1097/00001756-200303240-00016 · Cited by 54
Tokuda, T., Tamaoka, A., Matsuno, S., Sakurai, S., Shimada, H., Morita, H., & Ikeda, S. (2001) · Annals of Neurology · doi:10.1002/ana.112 · Cited by 41
Ueno, I., Sakai, T., Yamaoka, M., Yoshida, R., & Tsugita, A. (2000) · Electrophoresis · doi:10.1002/(sici)1522-2683(20000501)21:9<1832::aid-elps1832>3.0.co;2-7 · Cited by 38
Baker, L. D., Sambamurti, K., Craft, S., Cherrier, M., Raskind, M. A., Stanczyk, F. Z., Plymate, S. R., & Asthana, S. (2003) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.11.2.239 · Cited by 38
Genotyping of Apolipoprotein E : Comparative Evaluation of Different Protocols
Ingelsson, M., Shin, Y., Irizarry, M. C., Hyman, B. T., Lilius, L., Forsell, C., & Graff, C. (2003) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0914s38 · Cited by 37
Self-citationBuxbaum, J. D. (2002) · Frontiers in bioscience · doi:10.2741/buxbaum · Cited by 36
Alzheimer Disease–Related Abnormalities of Amyloid β Precursor Protein Isoforms in the Platelet
Bush, A. I., & Tanzi, R. E. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1179 · Cited by 34
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients
Baskin, F., Rosenberg, R. N., Fang, X. T., Hynan, L. S., Moore, C. B., Weiner, M., & Vega, G. L. (2003) · Neurology · doi:10.1212/01.wnl.0000068029.56740.96 · Cited by 30
Ramharack, R., Spahr, M. A., Kreick, J. S., & Sekerke, C. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37567-2 · Cited by 26
High cholesterol affects platelet APP processing in controls and in AD patients
Borroni, B., Colciaghi, F., Lenzi, G. L., Caimi, L., Cattabeni, F., Luca, M. D., & Padovani, A. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00190-2 · Cited by 25
Lipoprotein(a) and Cognitive Performances in an Elderly White Population
Sarti, C., Pantoni, L., Pracucci, G., Carlo, A. D., Vanni, P., & Inzitari, D. (2001) · Stroke · doi:10.1161/01.str.32.7.1678 · Cited by 25
Fukumoto, H., Asami-Odaka, A., Suzuki, N., Shimada, H., Ihara, Y., & Iwatsubos, T. (1996) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)80532-x · Cited by 19
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
The Alzheimer's Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.008 · Cited by 1,525
Alzheimer’s Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2007) · Advances in Behavioral Biology · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,468
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Metadata
- Authors
- Irizarry, M. C.
- Venue
- NeuroRX
- Published
- 2004-04
- Volume
- 1
- Issue
- 2
- Pages
- 226-234
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2077966741
- Cited by
- 268
- References
- 118
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.